Tablets explicitly designed for weight reduction might be an excellent choice for those who want to get rid of excess weight in a hurry without having to make significant changes to their eating ...
Irritable bowel syndrome with constipation (IBS-C) is characterized by symptoms such as irregular bowel movements, abdominal pain, and bloating. The U.S. Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . Ironwood Pharmaceuticals Inc. announced positive results from its phase 3 trial that evaluated Linzess for the ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for ...
The U.S. Food and Drug Administration (FDA) granted priority review to AbbVie (NYSE:ABBV) and Ironwood Pharmaceuticals' (NASDAQ:IRWD) application seeking expanded approval of Linzess (linaclotide) to ...
Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children ...
(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD) announced the FDA has granted Priority Review to the supplemental New Drug Application for LINZESS for the treatment of children and adolescents ages ...
The US Food and Drug Administration has expanded its approval of Ironwood Pharmaceuticals' (NASDAQ:IRWD) drug Linzess to include the treatment of functional constipation in children and teens. Linzess ...